

# Atopic Dermatitis (Atopic Eczema) (Dermatology) - Drugs In Development, 2021

<https://marketpublishers.com/r/A4295BB78737EN.html>

Date: June 2021

Pages: 847

Price: US\$ 2,500.00 (Single User License)

ID: A4295BB78737EN

## Abstracts

Atopic Dermatitis (Atopic Eczema) (Dermatology) - Drugs In Development, 2021

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis - Drugs In Development, 2021, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.

Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis (Atopic Eczema) and features dormant

and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 9, 6, 57, 37, 4, 81, 28 and 8 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 7 and 3 molecules, respectively.

Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).

The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## Contents

Introduction

Atopic Dermatitis (Atopic Eczema) - Overview

Atopic Dermatitis (Atopic Eczema) - Therapeutics Development

Atopic Dermatitis (Atopic Eczema) - Therapeutics Assessment

Atopic Dermatitis (Atopic Eczema) - Companies Involved in Therapeutics Development

Atopic Dermatitis (Atopic Eczema) - Drug Profiles

Atopic Dermatitis (Atopic Eczema) - Dormant Projects

Atopic Dermatitis (Atopic Eczema) - Discontinued Products

Atopic Dermatitis (Atopic Eczema) - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Atopic Dermatitis (Atopic Eczema), 2021  
Number of Products under Development by Companies, 2021  
Number of Products under Development by Universities/Institutes, 2021  
Products under Development by Companies, 2021  
Products under Development by Universities/Institutes, 2021  
Number of Products by Stage and Target, 2021  
Number of Products by Stage and Mechanism of Action, 2021  
Number of Products by Stage and Route of Administration, 2021  
Number of Products by Stage and Molecule Type, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by 3SBio Inc, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by Abate Med Inc, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by AbbVie Inc, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by Abeome Corp, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by Aclaris Therapeutics Inc, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by Adare Pharma Solutions, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by Akaal Pharma Pty Ltd, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by Akeso Inc, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by Alexion Pharmaceuticals Inc, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by Allergy Therapeutics Plc, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by Almirall SA, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by Amgen Inc, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by Amicogen Inc, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by Amorepacific Corp, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by Amytrx Therapeutics Inc, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by Annji Pharmaceutical Co Ltd, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by AOBiome LLC, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by Apimeds Inc, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by Arcutis Biotherapeutics Inc, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by Arena Pharmaceuticals Inc, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by Arrien Pharmaceuticals LLC, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by Asana BioSciences LLC, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by Aslan Pharmaceuticals Ltd, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by Astellas Pharma Inc, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by AstraZeneca Plc, 2021  
Atopic Dermatitis (Atopic Eczema) - Pipeline by Atrapos Therapeutics LLC, 2021



## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Atopic Dermatitis (Atopic Eczema), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021



## I would like to order

Product name: Atopic Dermatitis (Atopic Eczema) (Dermatology) - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/A4295BB78737EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A4295BB78737EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970